John G. Fort
YOU?
Author Swipe
View article: Risk Factors for Graft Failure in Children Undergoing Hematopoietic Cell Transplant (HCT) for Hemoglobinopathies, Bone Marrow Failure Syndromes, Severe Aplastic Anemia, Inborn Errors of Metabolism and Primary Immune Deficiencies
Risk Factors for Graft Failure in Children Undergoing Hematopoietic Cell Transplant (HCT) for Hemoglobinopathies, Bone Marrow Failure Syndromes, Severe Aplastic Anemia, Inborn Errors of Metabolism and Primary Immune Deficiencies Open
Introduction: Autologous stem cell transplantation (ASCT) with high-dose melphalan (HDM) is the standard consolidation treatment for transplant-eligible multiple myeloma (MM) patients. Many countries use generic melphalan (MEL) due to its …
View article: 170 Social and Environmental Benefits of Virtual Fracture Clinics in Trauma and Orthopaedic Surgery: Reduced Patient Travel Time, Patient Cost and Air Pollutant Emissions
170 Social and Environmental Benefits of Virtual Fracture Clinics in Trauma and Orthopaedic Surgery: Reduced Patient Travel Time, Patient Cost and Air Pollutant Emissions Open
Aim Several papers have analysed the clinical benefits and safety of Virtual Fracture Clinics (VFCs). A significant increase in the use of Trauma and Orthopaedic (T&O) VFCs was seen during the COVID-19 pandemic. This study aims to investig…
View article: Long-term safety of naproxen and esomeprazole magnesium fixed-dose combination: phase III study in patients at risk for NSAID-associated gastric ulcers
Long-term safety of naproxen and esomeprazole magnesium fixed-dose combination: phase III study in patients at risk for NSAID-associated gastric ulcers Open
To evaluate long-term safety of enteric-coated naproxen 500 mg and immediate-release esomeprazole magnesium 20 mg fixed-dose combination (FDC) in patients at risk of NSAID-associated upper gastrointestinal (UGI) ulcers. In this open-label,…
View article: Long‐Term Safety of a Coordinated Delivery Tablet of Enteric‐Coated Aspirin 325 mg and Immediate‐Release Omeprazole 40 mg for Secondary Cardiovascular Disease Prevention in Patients at <scp>GI</scp> Risk
Long‐Term Safety of a Coordinated Delivery Tablet of Enteric‐Coated Aspirin 325 mg and Immediate‐Release Omeprazole 40 mg for Secondary Cardiovascular Disease Prevention in Patients at <span>GI</span> Risk Open
Summary Introduction In two, 6‐month, randomized, double‐blind Phase 3 trials, PA 32540 (enteric‐coated aspirin 325 mg and immediate‐release omeprazole 40 mg) compared to aspirin alone was associated with fewer endoscopic gastric and duode…